Ascendis Pharma authorizes $400 million share buyback program

COPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND) has authorized a $400 million share repurchase program, the company announced in a press release. The Board of Directors is authorized to buy back shares through various methods, including market purchases, private transactions, block trades, and accelerated repurchase programs. The timing and amount of repurchases will depend on market conditions, share price, and other factors.

The company is not obligated to buy back a specific number of shares and can modify, suspend, or terminate the program at any time without notice. Ascendis Pharma, headquartered in Copenhagen, Denmark, also has facilities in Europe and the United States. The biopharmaceutical company specializes in developing therapies using its TransCon technology platform.